Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference

AURA 11.26.2024

Full Press ReleaseSEC FilingsOur AURA Tweets

About Gravity Analytica

Recent News

  • 12.03.2024 - 7th Annual Evercore ISI HealthCONx Conference
  • 11.26.2024 - Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference
  • 11.12.2024 - Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights

Recent Filings

  • 01.21.2025 - 144 Report of proposed sale of securities
  • 01.21.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.03.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
PDF Version

BOSTON,Nov. 26, 2024(GLOBE NEWSWIRE) --Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the 7th AnnualEvercore ISI HealthCONx Conferenceon Tuesday, December 3, 2024, at 2:35 p.m. ET.

The live webcast of the fireside chat will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website athttps://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.

AboutAura Biosciences

Aura Biosciencesis a clinical-stage biotechnology company focused on developing precision therapies for solid tumors that aim to preserve organ function. Our lead candidate, bel-sar (AU-011), is currently in late-stage development for primary choroidal melanoma and in early-stage development in other ocular oncology indications and bladder cancer.Aura Biosciencesis headquartered inBoston, MA.Our mission is to grow as an innovative global oncology company that positively transforms the lives of patients.

For more information, visitaurabiosciences.com. Follow us on X (formerly Twitter) @AuraBiosciences and visit us on LinkedIn.

Investor Contact:Alex DasallaHead of Investor Relations and Corporate CommunicationsIR@aurabiosciences.com

Media Contact:Kimberly HaKKH Advisorskimberly.ha@kkhadvisors.com917-291-5744

Primary Logo

Source: Aura Biosciences, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com